Anaptysbio, Inc SEC filings ANAB

Anaptysbio, Inc has 725 filings in SEC EDGAR's recent list, going back to Jul 6, 2006. Its latest annual report, Form 10-KT, was filed on Sep 21, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 12, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026. The company's fiscal year ends on June 30.

Anaptysbio, Inc SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Jun 29, 2026 —
DEF 14A Proxy statement Jun 29, 2026 Jun 29, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 17, 2025
DEFA14A Additional proxy material Apr 24, 2024 —
DEF 14A Proxy statement Apr 24, 2024 Jun 12, 2024
DEFA14A Additional proxy material Apr 27, 2023 —
DEF 14A Proxy statement Apr 27, 2023 Jun 15, 2023
PRE 14A Preliminary proxy statement Apr 14, 2023 Apr 14, 2023
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 23, 2022
DEFA14A Additional proxy material Apr 26, 2021 —
DEF 14A Proxy statement Apr 26, 2021 Jun 17, 2021
DEFA14A Additional proxy material Apr 27, 2020 —
DEF 14A Proxy statement Apr 27, 2020 Jun 19, 2020
DEFA14A Additional proxy material Apr 26, 2019 —
DEF 14A Proxy statement Apr 26, 2019 Dec 31, 2018
DEFA14A Additional proxy material Apr 26, 2018 —
DEF 14A Proxy statement Apr 26, 2018 Jun 12, 2018

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANAB (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1370053
Former names
ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.